The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC
Ann Oncol
.
2018 Apr 1;29(4):1078.
doi: 10.1093/annonc/mdx478.
Authors
P N Aguiar Jr
1
,
L A Perry
2
,
J Penny-Dimri
2
,
H Babiker
3
,
H Tadokoro
4
,
R A de Mello
5
,
G L Lopes Jr
6
Affiliations
1
Doctoral Grade Fellowship, Clinical Oncology Sector, Faculdade de Medicina do ABC, Santo André, Brazil.
2
Faculty of Medicine, Monash University, Mildura, Australia.
3
Clinical Oncology Sector, Honor Health Scottsdale, Scottsdale, USA.
4
Clinical Oncology Sector, Universidade Federal de São Paulo, São Paulo, Brazil.
5
Clinical Oncology Sector, Universidade do Algarve, Faro, Portugal.
6
Clinical Oncology Sector at the University of Miami, Miami, USA.
PMID:
29267838
DOI:
10.1093/annonc/mdx478
No abstract available
Publication types
Published Erratum